Indoco Remedies (INDOCO) investor relations material

Executive summary

• Standalone operational revenue grew 5.8% year-over-year to INR 4,081 million; consolidated revenue rose 8.2% to INR 4,662 million.

• Consolidated Q1 FY27 revenue grew 6% year-over-year to ₹4,081 million, driven by resilient domestic formulations and steady international/API business performance.

• EBITDA margin improved to 10.3% on standalone basis, with consolidated EBITDA at 8.8%.

• A one-time gain of ₹9,734 lakhs from the sale of the Ophthalmic Business Division significantly impacted profit figures.

• Regulatory milestones achieved: E.U. GMP certifications for Baddi and Goa plants, and US FDA pre-approval inspection cleared with zero observations.

Financial highlights

• Standalone Q1 revenue from operations: ₹40,812 lakhs, up from ₹38,561 lakhs year-over-year.

• Standalone net profit for Q1: ₹8,232 lakhs, compared to a loss of ₹2,807 lakhs in Q1 last year, mainly due to the exceptional gain.

• Consolidated Q1 revenue from operations: ₹46,622 lakhs, up from ₹43,086 lakhs year-over-year.

• Consolidated net profit for Q1: ₹6,544 lakhs, compared to a loss of ₹3,635 lakhs in Q1 last year.

• Basic and diluted EPS (consolidated) for Q1: ₹7.09, versus negative ₹3.94 in Q1 last year.

Outlook and guidance

• Expectation of higher single-digit to double-digit growth in India business going forward.

• Targeting double-digit EBITDA margins for the year.

• Focus on scaling mid-size brands, expanding chronic segment, and leveraging R&D for high-value international filings.

• Anticipate continued improvement in margins and operational efficiency.

• Management emphasizes continued execution of long-term strategy and expects further growth from core businesses despite a dynamic environment.